Fischer, Luise
Grieb, Nora
Born, Patrick
Weiss, Ronald
Seiffert, Sabine
Boldt, Andreas
Fricke, Stephan
Franz, Paul
Heyn, Simone
Kubasch, Anne Sophie http://orcid.org/0000-0002-0747-4941
Baber, Ronny
Weidner, Heike
Wang, Song Yau http://orcid.org/0000-0001-5433-8750
Bach, Enrica
Hoffmann, Sandra
Ussmann, Jule
Kirchberg, Janine
Hell, Saskia
Schwind, Sebastian http://orcid.org/0000-0002-1315-2332
Metzeler, Klaus H. http://orcid.org/0000-0003-3920-7490
Herling, Marco
Jentzsch, Madlen http://orcid.org/0000-0002-2270-0804
Franke, Georg-Nikolaus
Sack, Ulrich
Reiche, Kristin http://orcid.org/0000-0002-4452-4872
Köhl, Ulrike
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Vucinic, Vladan http://orcid.org/0000-0002-8398-285X
Merz, Maximilian http://orcid.org/0000-0002-2805-5973
Article History
Received: 28 September 2023
Revised: 17 November 2023
Accepted: 15 December 2023
First Online: 6 January 2024
Competing interests
: SF: Consultant and/or speaker fees: Novartis Pharma GmbH, Janssen-Cilag GmbH, Vertex Pharmaceuticals (Germany) GmbH, Kite/Gilead Sciences GmbH, MSGO GmbH, Bristol-Myers Squibb GmbH & Co. KGaA. UK: Consultant and/or speaker fees: AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. KGaA. UP: Honoraria and research support: BMS, Johnson-Johnson, Gilead. MM: Advisory Boards/Honoraria/Research support: Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks and Takeda.